Gene: RNF139
Official Full Name: ring finger protein 139provided by HGNC
Gene Summary: The protein encoded by this gene is a multi-membrane spanning protein containing a RING-H2 finger. This protein is located in the endoplasmic reticulum, and has been shown to possess ubiquitin ligase activity. This gene was found to be interrupted by a t(3:8) translocation in a family with hereditary renal and non-medulary thyroid cancer. Studies of the Drosophila counterpart suggested that this protein may interact with tumor suppressor protein VHL, as well as with COPS5/JAB1, a protein responsible for the degradation of tumor suppressor CDKN1B/P27KIP. [provided by RefSeq, Jul 2008]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO06254 | RNF139 Knockout cell line (HeLa) | Human | RNF139 | 1:3~1:6 | Negative | Online Inquiry |
KO06255 | RNF139 Knockout cell line (HCT 116) | Human | RNF139 | 1:2~1:4 | Negative | Online Inquiry |
KO06256 | RNF139 Knockout cell line (HEK293) | Human | RNF139 | 1:3~1:6 | Negative | Online Inquiry |
KO06257 | RNF139 Knockout cell line (A549) | Human | RNF139 | 1:3~1:4 | Negative | Online Inquiry |
RNF139 Gene Knockout Cell Lines are a specialized tool created to facilitate the study of the RNF139 protein and its biological implications. These cell lines have been engineered using advanced CRISPR/Cas9 technology to achieve a precise knockout of the RNF139 gene, which encodes an E3 ubiquitin ligase involved in various cellular processes, including protein degradation, cell cycle regulation, and DNA repair mechanisms. By eliminating RNF139 expression, researchers can investigate the protein's role in pathology, including cancer proliferation and neurodegenerative diseases.
The key mechanism underlying the functionality of the RNF139 Gene Knockout Cell Lines lies in the CRISPR/Cas9 gene-editing system, which allows for targeted and efficient modification of genomic DNA. This breakthrough technology ensures a high specificity of the knockout, minimizing off-target effects and allowing for reliable results in subsequent experiments. This precision is critical in elucidating the cellular pathways and molecular interactions associated with RNF139, thus paving the way for new therapeutic pathways.
In scientific research, these knockout cell lines serve as invaluable models for functional studies, drug screening, and biomarker identification. Their application extends beyond basic biology to clinical settings, where understanding RNF139's unique role could inform novel treatment strategies for diseases linked to its dysregulation.
Compared to conventional knockout techniques or RNAi-based approaches, the RNF139 Gene Knockout Cell Lines offer superior efficiency, stability, and ease of use. Researchers gain immediate access to a robust platform that empowers them to validate hypotheses and generate reproducible data without the complexities often associated with other gene-editing methods.
For researchers and clinicians keen on unraveling the complexities of cellular regulation and disease mechanisms, the RNF139 Gene Knockout Cell Lines present a cutting-edge solution. Our commitment to excellence is reinforced by our expertise in genetic engineering and cellular biology, ensuring you have access to the highest quality products that support groundbreaking research and clinical advancements.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.